Assessing the cost-effectiveness of pharmacogenomics.
Veenstra, D L
Assessing the cost-effectiveness of pharmacogenomics. [electronic resource] - AAPS pharmSci 2000 - E29 p. digital
Publication Type: Comparative Study; Journal Article
1522-1059
10.1208/ps020329 doi
Anticholesteremic Agents--therapeutic use
Anticoagulants--pharmacokinetics
Antimetabolites, Antineoplastic--therapeutic use
Cardiovascular Diseases--drug therapy
Carrier Proteins--genetics
Child
Cholesterol Ester Transfer Proteins
Cost-Benefit Analysis
Drug Therapy--economics
Genotype
Glycoproteins
Hepatitis C--drug therapy
Humans
Interferons--therapeutic use
Mercaptopurine--therapeutic use
Methyltransferases--deficiency
Pharmacogenetics--economics
Pharmacology, Clinical--economics
Phenotype
Pravastatin--therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Ribavirin--therapeutic use
Warfarin--pharmacokinetics
Assessing the cost-effectiveness of pharmacogenomics. [electronic resource] - AAPS pharmSci 2000 - E29 p. digital
Publication Type: Comparative Study; Journal Article
1522-1059
10.1208/ps020329 doi
Anticholesteremic Agents--therapeutic use
Anticoagulants--pharmacokinetics
Antimetabolites, Antineoplastic--therapeutic use
Cardiovascular Diseases--drug therapy
Carrier Proteins--genetics
Child
Cholesterol Ester Transfer Proteins
Cost-Benefit Analysis
Drug Therapy--economics
Genotype
Glycoproteins
Hepatitis C--drug therapy
Humans
Interferons--therapeutic use
Mercaptopurine--therapeutic use
Methyltransferases--deficiency
Pharmacogenetics--economics
Pharmacology, Clinical--economics
Phenotype
Pravastatin--therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Ribavirin--therapeutic use
Warfarin--pharmacokinetics